That seems far too conservative.
a better approach is to determine the demand of a product and what clinical data has determined and determine if the product is good.
your approach would leave a lot of people buying a company overvalued. By the time a product is announced approved commercialisation you've lost all the upside.
look at beam therapeutics. Only a P1 asset, but already valued at 2.1b US. Obviously, a different market being Nasdaq, but application is similar.
RAC - Charts & Price Action, page-19040
-
- There are more pages in this discussion • 3,565 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |